Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Codexis, Inc. stock logo
CDXS
Codexis
$1.56
-2.5%		$2.09
$0.96
▼
$3.26
$175.21M2.541.64 million shs1.24 million shs
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
$4.69
-4.1%		$4.37
$3.28
▼
$6.18
$635.62M1.17804,353 shs927,484 shs
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
$106.04
-6.3%		$100.64
$58.83
▼
$115.52
$633.45M0.92147,868 shs161,033 shs
OmniAb, Inc. stock logo
OABI
OmniAb
$3.38
-1.5%		$2.35
$1.30
▼
$3.63
$496.60M0.45646,012 shs553,941 shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Codexis, Inc. stock logo
CDXS
Codexis
-2.50%+6.12%-29.41%-36.59%-48.85%
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
-4.09%+11.67%+0.86%+37.94%+12.47%
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
-6.33%+3.30%+12.00%+9.92%+53.06%
OmniAb, Inc. stock logo
OABI
OmniAb
-1.46%+9.74%+62.50%+55.05%+64.88%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Codexis, Inc. stock logo
CDXS
Codexis
$1.56
-2.5%		$2.09
$0.96
▼
$3.26
$175.21M2.541.64 million shs1.24 million shs
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
$4.69
-4.1%		$4.37
$3.28
▼
$6.18
$635.62M1.17804,353 shs927,484 shs
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
$106.04
-6.3%		$100.64
$58.83
▼
$115.52
$633.45M0.92147,868 shs161,033 shs
OmniAb, Inc. stock logo
OABI
OmniAb
$3.38
-1.5%		$2.35
$1.30
▼
$3.63
$496.60M0.45646,012 shs553,941 shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Codexis, Inc. stock logo
CDXS
Codexis
-2.50%+6.12%-29.41%-36.59%-48.85%
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
-4.09%+11.67%+0.86%+37.94%+12.47%
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
-6.33%+3.30%+12.00%+9.92%+53.06%
OmniAb, Inc. stock logo
OABI
OmniAb
-1.46%+9.74%+62.50%+55.05%+64.88%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Codexis, Inc. stock logo
CDXS
Codexis
2.00
Hold$5.00220.51% Upside
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
2.33
Hold$5.5618.60% Upside
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
2.00
Hold$110.003.73% Upside
OmniAb, Inc. stock logo
OABI
OmniAb
2.00
HoldN/AN/A

Current Analyst Ratings Breakdown

Latest CDXS, MLAB, CTKB, and OABI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/14/2026
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetEqual Weight$94.00 ➝ $110.00
8/11/2026
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D) ➝ Hold (C-)
8/7/2026
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$5.00
8/6/2026
OmniAb, Inc. stock logo
OABI
OmniAb
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/21/2026
OmniAb, Inc. stock logo
OABI
OmniAb
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/20/2026
Codexis, Inc. stock logo
CDXS
Codexis
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
6/24/2026
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
6/18/2026
OmniAb, Inc. stock logo
OABI
OmniAb
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
6/17/2026
Codexis, Inc. stock logo
CDXS
Codexis
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight
6/3/2026
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D+) ➝ Sell (D)
6/2/2026
OmniAb, Inc. stock logo
OABI
OmniAb
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
(Data available from 8/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Codexis, Inc. stock logo
CDXS
Codexis
$70.39M2.43N/AN/A$0.30 per share5.20
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
$201.49M3.03N/AN/A$2.48 per share1.89
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
$249.13M2.38$11.03 per share9.61$33.73 per share3.14
OmniAb, Inc. stock logo
OABI
OmniAb
$18.67M26.21N/AN/A$1.80 per share1.88
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Codexis, Inc. stock logo
CDXS
Codexis
-$43.97M-$0.37N/AN/AN/A-39.55%-74.36%-23.58%10/29/2026 (Estimated)
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
-$66.54M-$0.62N/A234.50N/A-38.98%-12.40%-9.17%N/A
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
$6.71M$0.84126.24N/AN/A1.92%22.72%9.82%N/A
OmniAb, Inc. stock logo
OABI
OmniAb
-$64.78M-$0.36N/AN/AN/A-115.12%-16.59%-14.82%11/3/2026 (Estimated)

Latest CDXS, MLAB, CTKB, and OABI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2026Q2 2026
Codexis, Inc. stock logo
CDXS
Codexis
-$0.1417-$0.13+$0.0117-$0.13$13.82 million$14.92 million
8/10/2026Q1 2027
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
N/A$2.68N/A$0.49N/A$60.14 million
8/6/2026Q2 2026
OmniAb, Inc. stock logo
OABI
OmniAb
-$0.12-$0.05+$0.07-$0.05$4.69 million$13.42 million
8/5/2026Q2 2026
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
-$0.0933-$0.09+$0.0033-$0.09$47.31 million$48.14 million
5/27/2026Q4 2026
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
$1.78$1.53-$0.25-$0.75$65.21 million$63.72 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Codexis, Inc. stock logo
CDXS
Codexis
N/AN/AN/AN/AN/A
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
N/AN/AN/AN/AN/A
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
$0.640.60%N/A76.19%N/A
OmniAb, Inc. stock logo
OABI
OmniAb
N/AN/AN/AN/AN/A

Latest CDXS, MLAB, CTKB, and OABI Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/6/2026
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
quarterly$0.160.62%8/31/20268/31/20269/15/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Codexis, Inc. stock logo
CDXS
Codexis
1.03
3.06
5.23
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
N/A
4.48
3.86
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
0.73
1.79
1.29
OmniAb, Inc. stock logo
OABI
OmniAb
N/A
4.80
4.80

Institutional Ownership

CompanyInstitutional Ownership
Codexis, Inc. stock logo
CDXS
Codexis
78.54%
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
69.46%
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
90.60%
OmniAb, Inc. stock logo
OABI
OmniAb
72.08%

Insider Ownership

CompanyInsider Ownership
Codexis, Inc. stock logo
CDXS
Codexis
3.50%
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
10.36%
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
2.80%
OmniAb, Inc. stock logo
OABI
OmniAb
9.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Codexis, Inc. stock logo
CDXS
Codexis
250109.51 million105.67 millionOptionable
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
500129.98 million116.52 millionOptionable
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
6805.60 million5.44 millionNot Optionable
OmniAb, Inc. stock logo
OABI
OmniAb
7144.78 million130.59 millionOptionable

Recent News About These Companies

Dimensional Fund Advisors LP Has $2.74 Million Stake in OmniAb, Inc. $OABI
August 14 at 3:27 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-dimensional-fund-advisors-lp-has-274-million-stake-in-omniab-inc-oabi-2026-08-14/
OmniAb (NASDAQ:OABI) Sets New 1-Year High - Time to Buy?
August 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/omniab-nasdaqoabi-sets-new-1-year-high-time-to-buy-2026-08-11/
OmniAb, Inc. (OABI) Stock Earnings Call Transcripts - Yahoo Finance
August 11, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/quote/OABI/earnings-calls/
HC Wainwright Forecasts OmniAb's Q3 Earnings (NASDAQ:OABI)
August 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/hc-wainwright-forecasts-omniabs-q3-earnings-nasdaqoabi-2026-08-11/
OmniAb, Inc. (OABI) Latest Stock News & Headlines - Yahoo Finance
August 9, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/quote/OABI/news/
OmniAb (NASDAQ:OABI) Jumps After Strong Quarterly Update
August 9, 2026  |  kalkinemedia.comK
OmniAb (NASDAQ:OABI) Issues Quarterly Earnings Results, Beats Expectations By $0.07 EPS
August 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/omniab-nasdaqoabi-issues-quarterly-earnings-results-beats-expectations-by-007-eps-2026-08-08/
OmniAb Q2 Earnings Call Highlights
August 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/omniab-q2-earnings-call-highlights-2026-08-07/
OmniAb, Inc. (OABI) Reports Q2 Loss, Beats Revenue Estimates
August 6, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2970514/omniab-inc-oabi-reports-q2-loss-beats-revenue-estimates?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_4-2970514
OmniAb Reports Second Quarter 2026 Financial Results and Business Highlights
August 6, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260806690841/en/omniab-reports-second-quarter-2026-financial-results-and-business-highlights/
OmniAb (OABI) to Post Earnings on Thursday
July 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/omniab-oabi-to-post-earnings-on-thursday-2026-07-30/
VERAXA Biotech (NASDAQ: VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration
July 27, 2026  |  usatoday.comhttps://www.usatoday.com/press-release/story/38339/veraxa-biotech-nasdaq-vrxa-advances-bispecific-adc-program-under-omniab-collaboration/
VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb
July 27, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/veraxa-biotech-announces-advancement-of-novel-bispecific-antibody-drug-conjugate-program-vxa-222-from-joint-discovery-collaboration-with-omniab-1036366594
VERAXA Biotech Announces Advancement of VXA-222 Bispecific ADC Program in Collaboration with OmniAb
July 27, 2026  |  quiverquant.comQ
OmniAb to Report Second Quarter 2026 Financial Results on August 6
July 16, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260716057438/en/omniab-to-report-second-quarter-2026-financial-results-on-august-6/
OmniAb Names Amechi Nwachuku Chief Operating Officer
July 13, 2026  |  aol.comA
OmniAb (OABI) Gains More Than 38% Over 6 Months, Can It Go Higher?
July 3, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/omniab-oabi-gains-more-than-38-over-6-months-can-it-go-higher-1794177/
OmniAb (NASDAQ:OABI) Cash Burn Looks Manageable
June 30, 2026  |  kalkinemedia.comK
OmniAb Shareholders Approve Directors and Auditor at Meeting
June 18, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/omniab-shareholders-approve-directors-and-auditor-at-meeting?utm_source=marketbeat.com&utm_medium=referral
Why Is OmniAb Gaining Attention In The Biotechnology Landscape?
June 18, 2026  |  kalkinemedia.comK
OABI Share News Today
June 4, 2026  |  uk.investing.comhttps://uk.investing.com/equities/avista-public-acquisition-ii-news

New MarketBeat Followers Over Time

Media Sentiment Over Time

Codexis stock logo

Codexis NASDAQ:CDXS

$1.56 -0.04 (-2.50%)
As of 08/14/2026 04:00 PM Eastern

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

Cytek Biosciences stock logo

Cytek Biosciences NASDAQ:CTKB

$4.69 -0.20 (-4.09%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$4.61 -0.08 (-1.75%)
As of 08/14/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

Mesa Laboratories stock logo

Mesa Laboratories NASDAQ:MLAB

$106.04 -7.16 (-6.33%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$106.16 +0.11 (+0.11%)
As of 08/14/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. The Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. The Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems, offered under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.

OmniAb stock logo

OmniAb NASDAQ:OABI

$3.38 -0.05 (-1.46%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$3.32 -0.06 (-1.78%)
As of 08/14/2026 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

OmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas